Please write a 150 word peer response for Answer 1 and another 150 word peer response for Answer 2.
Correlation between Fertility Drugs and Ovarian Cancer
According to the discussion in the article fertility drugs, Serophene and personal are leading to increasing the risk of getting ovarian cancer by three times. But I would not like to support the data given in the article because the data provided is based on very small sample size. Conducting the survey and providing the results should be based on clear and proper conclusions. But providing the conclusions on the basis of insufficient information is not valid. Any information provided should be based on clear analysis and a proper survey (Hegazy, 2020).
The decisions or conclusions draw on the small sample size would be less accurate compared to the conclusions drawn on the basis of the large sample size. In the case of conclusions drawn in the American journal of epidemiology, the sample size was very small. So the conclusion is given that fertility drugs cause three times the risk for ovarian cancer is not absolute. There were many other conclusions drawn on this case it has stated that there are not that much effect or risks because of this fertility drug (Tomao, 2014).
Many preventive measures and proper care are taken for the women for proper conceiv for the women who are suffering from non-conceiving. In some cases, if proper measures are not suitable it may cause obesity and some of the cancer types. But the risk In the case of fertility drug giving nowadays many measures are given and the chance for risk is very low. In fact, it was given that more effect is caused due to the infertility drug. And many of the articles provided to present the effect or provide a warning regarding the effect it causes. Yes, there is a correlation between both the fertility drugs and ovarian cancer but it is very least or low correlated. Even though there is an increase in fertility drugs there may not be that much affected on ovarian cancer. The fertility drugs not only cause ovarian cancer but also may cause obesity, breast cancer etc. This is all about the correlation between fertility drugs and ovarian cancer (Vlahos, 2010).
Hegazy, A. A. (2020). Is There any Mean to Postpone The Menopausal Ovarian Senescence? International Journal of Fertility & Sterility, 13(4), 346–347. https://doi.org/10.22074/ijfs.2020.5797
Tomao, F., Lo Russo, G., Spinelli, G. P., Stati, V., Prete, A. A., Prinzi, N., Sinjari, M., Vici, P., Papa, A., Chiotti, M. S., Panici, P. B., & Tomao, S. (2014). Fertility drugs, reproductive strategies and ovarian cancer risk. Journal of Ovarian Research, 7(1), 1–19. https://doi.org/10.1186/1757-2215-7-51
Vlahos, N. F., Economopoulos, K. P., & Creatsas, G. (2010). Fertility drugs and ovarian cancer risk: a critical review of the literature. Annals of the New York Academy of Sciences, 1205(1), 214–219. https://doi.org/10.1111/j.1749-6632.2010.05668.x
Use of Fertility Drugs and Ovarian Cancer
Ovarian cancer is the most common cancer and is ranked as fifth place. In the United States, this kind of cancer has resulted in death in many females. In the study, it is stated that the use of drugs like Pergonal and Serophene will increase the rick up to three times in causing ovarian cancer. The issue is too serious that the fertility drugs should be stopped using but the manufacturing of such drugs is not stopped. The women should have the right to known the data regarding the kind of drugs (Charpentier & et al, 2014)being used and the result or the side effects caused due to it. There are no such laws that state to disclose the data that is required to know for the one how uses the drug. The balance regarding the ethical test is lost. It is ethical to known how are we treated in the name of treatment regarding the uses of drugs.
There is nothing in the hiding of the direction of manufacturing. There should be a full discloser of information in the market so the buyers can make the choice in selecting what they are buying. When it comes to making the decision it has become one-sided for taking the decision for selecting what they want. It is observed in clear that the buyers are not even getting the required data for buying the product rather than what data is present with the drug firm (Gadducci, & et al, 2013). Comparatively the drug firm has more data than the others or the purchasers having it. With the history of what they having the firms are very good at financial analysis if they are able to disclose some data that is to hide some important data that is not being disclosed so that they allow the market by hiding some data.
If the firms are able to withstand the data so that they can later defend what they want on the product liability suits. It is very important to make the disclosure it is not just an ethical view but also the financial beneficiary and the litigation perspective. As asked in question I would say my answer is no. if I am manufacturing the drug-like Pergonal and Serophene I will not disclose any study information regarding the manufacturing. There is no statement regarding that stated the study is provided on the basis that the data is provided on the large sample. It is ethical and needs to give information regarding the drugs (Vlahos, & et al, 2010) because ovarian cancer caused by the drugs needed to be understood and the dosage of usage acceptable should also be mentioned.
Charpentier, A.-M., Chong, A. L., Gingras-Hill, G., Ahmed, S., Cigsar, C., Gupta, A. A., Greenblatt, E., & Hodgson, D. C. (2014). Anti-Müllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer. Journal of Cancer Survivorship, 8(4), 548–554. https://doi.org/10.1007/s11764-014-0364-4
Gadducci, A., Guerrieri, M. E., & Genazzani, A. R. (2013). Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecological Endocrinology, 29(1), 30–35. https://doi.org/10.3109/09513590.2012.705382
Vlahos, N. F., Economopoulos, K. P., & Creatsas, G. (2010). Fertility drugs and ovarian cancer risk: a critical review of the literature. Annals Of The New York Academy Of Sciences, 1205, 214–219. https://doi.org/10.1111/j.1749-6632.2010.05668.x